Acer Therapeutics: Multiple Aces Up Its Sleeve

Summary

  • Acer announced on December 26, 2018 that the FDA had accepted Acer's NDA for EDSIVO for review for the treatment of vEDS.
  • The FDA also granted priority review of the EDSIVO NDA with a PDUFA target action date of June 25, 2019.
  • On January 2, 2019 Acer announced an in-licensing deal for the world wide rights to osanetant from Sanofi without much detail being provided.
  • Osanetant, a clinical stage NKR receptor antagonist, may have substantial value as a potential treatment for certain neuroendocrine-related disorders.
  • Acer has multiple upcoming catalysts in 2019 including the potential FDA approval and commercial launch of EDSIVO.

Acer Therapeutics

ChartData by YCharts

Acer Therapeutics Inc. (NASDAQ: ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on orphan and ultra-orphan diseases with significant unmet need. I also described in some detail the background and market potential of Acer's first two late stage clinical drug candidates for the U.S. market for severe genetic disorders:

READ FULL ARTICLE HERE